Supplemental legends and figures

Assessment of glucocorticoid-induced enhancer activity of eSNP regions using STARR-seq reveals novel molecular mechanisms in psychiatric disorders

Signe Penner-Goeke[1,2], Melissa Bothe[3], Nils Kappelmann[1,4], Peter Kreitmaier[5], Ezgi Kaya[1,2], Dorothee Pöhlchen[1,4], Anne Kühnel[1,4], Darina Czamara[1], BeCOME working group, Laura V. Glaser[3], Simone Roeh[1], Maik Ködel[1], Jose Monteserin-Garcia[1], Christine Rummel[1,4], Janine Arloth-Knauer[1], Laura Diener-Hölzl[1], Barbara Woelfel[1], Susann Sauer[1], Stephan Riesenberg[7], Michael J. Ziller[1,8], Marta Labeur[1], Sebastiaan H. Meijsing[3,6], Elisabeth B. Binder[1*]

Supplementary Figures

Figure S1. Transcriptional response to dex of GR target genes. Fold changes of expression for three canonical GR-target genes (*FKBP5, SGK1, TSC22D3)* after dex treatment in cells lines as indicated: **A,** U2OS-GR, **B,** U138MG, **C,** induced pluripotent stem cells (IPSCs), **D,** neural precursor cells (NPCs) and E) iNeurons derived from IPSCs from two individuals. Mean expression relative to *GAPDH* ± S.D. is shown, dots depict values for individual data points. One-sided unpaired T-test, * p-value <0.05, ** p-value < 0.01 as compared to expression changes in the control transcript YWHAZ.

Figure S2. Quality controls of STARR-seq experiments. A, Principal component analysis of the biological replicates and **B,** Pearson's R^2 between biological replicates in the veh and **C,** dex condition for U2OS-GR cells. **D,** Principal component analysis of the biological replicates and **E,** Pearson's R^2 between biological replicates in the veh and **F,** dex condition for U138MG cells.

Figure S3. Enrichment in enhancer sites across tissues. ChromHMM enrichment of DREs predicted to be located within enhancer regions across different tissues compared to randomly selected matched SNPs. * FDR < 0.05; ** FDR< 0.01; permutation FDR.

Figure S4. Validation of STARR-seq results using qPCR. A, Individual fragments of three SNP-DREs were tested for activity in dex and veh conditions to determine the fold activation upon dex treatment. Two of the three variant-DREs displayed significant allele dependent differences in the dex condition (paired, one-sided t-test). **B,** The dex-induced activity for two DRE controls and two STARR-seq identified DREs was tested. Each region showed significant dex-dependent increases in activity when compared to negative control region in the direction observed in the STARR-seq. * p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001. Multiple comparisons test on dex vs. veh normalized Ct values.

Figure S5. Transcriptional response in response to dex in KO cell lines. Fold changes of expression for three canonical GR-target genes (*FKBP5, SGK1, TSC22D3)* after dex treatment in WT and **A**, rs12206258 DRE KO **B**, rs35288741 DRE KO cell lines. Note that *TSC22D3* contains a FOXC1 binding site in its promoter, possibly related to the reduced induced of that gene in the KO cells. **C**, Fold changes of transcripts located near rs35288741 in WT and KO cells. NE refers to transcripts not expressed. **D,** Schematic depicting the genomic locus containing an eSNP bin (highlighted orange) in relation to its predicted target gene, *NUAK2* (red box) and surrounding genes. Black box provides a zoomed-in view of the region containing the repressive SNP-DRE rs35288741 with the CRISPR/Cas9-deleted region highlighted in blue. Black dot represents a flanking eSNP not targeted. *p-value < 0.05; ** p-value < 0.01; *** p-value < 0.001, **** p-value < 0.0001, one-sided paired t-test on dex vs. veh normalized Ct values.

Fig. S6: Number of PheWAS associations after multiple comparison correction for the top 10 exposures with most associations. Results are categorised by outcome trait category. The y-axis describes the proxy SNP for MR analysis (left side) and associated gene (right side). The x-axis shows the number of PheWAS associations. Points are coloured by functional group.

Tables

Table S1. Genomic coordinates (hg19) and allele information for the 3662 eSNPs included in the STARR-seq.

Table S2. Dex regulatory elements (DREs) identified in STARR-seq. Effect sizes for the 508 and 66 DREs identified in the U2OS-GR and U138MG cells for the oligonucleotide harboring the reference and alternative alleles. NS refers to DREs only displaying significant dex-responsive activity in either the reference or alterative allele.

Table S3. Motifs significantly enriched within inductive and repressive dex regulatory elements using the Jaspar vertebrate motif database and random human promoters as a background model.

Table S4. Allele dependent dex-responsive elements (SNP-DREs) identified in STARR-seq. Effect sizes for the allele-dependent DREs identified in the U2OS-GR and U138MG cells in the dex and veh conditions. NS refers to SNP-DREs only displaying significant allele-dependent differential activity either the dex or veh condition.

Table S5. Transcripts regulated by DREs and associations with psychiatric disorders. Number of DREs and SNP-DREs identified as functional using STARR-seq. Associated disorder refers to disorder in which the transcript is differentially expressed in post-mortem tissues of subjects with specific psychiatric disorders.[30]

Table S6. Mendelian Randomization using SNP-DREs and meta-GWAS on psychopathology. Cross disorder meta-analysis beta and p-values were derived from the meta-GWAS summary statistics[31] and Mendelian Randomization results for those SNP-DREs showing a significant putative causal effect on psychopathology.

Table S7. Unique phenotype with corresponding trait category with significant associations in PheWAS MR analyses.

Table S8. Number of PheWAS MR associations across outcome trait categories.

Table S9. SNPs used to generate the functional gene score and their respective weightings from the STARR-Seq experiment.

Table S10. Primer sequences used for dex-induced gene expression analyses, STARR-seq, and the endogenous and exogenous validation experiments.

Table S11. List of authors within the BeCOME working group.

Figure S1


A
B
C
D
E
Fold change (dex/veh)
YWHAZ
FKBP5
Sgk1
TSC22D3
U2OS-GR
U138MG
IPSC
NPCs
iNeurons
* p-value ≤ 0.05
** p-value ≤ 0.01
*** p-value ≤ 0.001
**** p-value ≤ 0.0001

.

Figure S2


A
PCA_2(16.5%)
PCA_1(64.3%)
R1_veh
R3_veh
R2_veh
R1_dex
R2_dex
R3_dex
B
Veh
R^2 = 0.87
R3_veh
R2_veh
C
Dex
R^2 = 0.9
R3_dex
R2_dex
D
PCA_2(2.5%)
PCA_1(96.6%)
R2_veh
R1_veh
R2_dex
R1_dex
E
Dex
R^2 = 1
R2_dex
R1_dex
F
Veh
R^2 = 0.99
R2_veh
R1_veh

Figure S3


Spleen
Blood
Pancreas
Bone
Heart
Skin
Breast
Mesenchymal Stem Cell Derived
Brain
Gastrointestinal
Adrenal
Lung
Placenta
Embryonic stem cell-derived
Vascular
Muscle
Fat
Liver
**
0
1
2
3
Fold enrichment

Figure S4


A
rs382964
rs9525228
rs9274181
Fold change (dex/veh)
2.0
1.5
1.0
0.5
0.0
ref
alt
*
ns
B
***
**
80
60
40
20
0
neg_region_control
dex_control_1
dex_control_2
rs9270467
rs11773628

Figure S5


A
Fold change (dex/veh)
40
30
20
10
0
ns
ns
ns
FKBP5
TSC22D3
Sgk1
B
Fold change (dex/veh)
40
30
20
10
0
****
ns
ns
FKBP5
TSC22D3
Sgk1
C
Fold change (dex/veh)
5
0
-5
-10
-15
ns
NE
ns
ns
****
ns
*
NFASC
CNTN2
TMEM81
RBBP5
DSTYK
TMCC2
NUAK2
WT
KO

D
chr1
203.1Mb
203.2Mb
203.3Mb
203.4Mb
203.5Mb
NFASC
CNTN2
TMEM81
RBBP5
DSTYK
TMCC2
NUAK2
rs7534993
rs35288741
chr1
203.191Mb
203.192Mb
203.193Mb
203.194Mb
203.195Mb

Figure S6


All traits
rs34928543 HLA-DRB4
rs9275314 HLA-DRB4
rs9271161 HLA-DRB5
rs9270678 HLA-DRB5
rs9271171 HLA-DRB5
rs35375092 GPX1
rs4970988 RFX5
rs6657388 RFX5
rs28746802 HLA-DRB4
rs3826440 RPL26
50 75 100 125 150 175
No. of Associations
Biomarker
rs34928543 HLA-DRB4
rs9275314 HLA-DRB4
rs10793957 RPL7A
rs3826440 RPL26
rs35375092 GPX1
rs9270678 HLA-DRB5
rs4970988 RFX5
rs9271161 HLA-DRB5
rs103947 ANXA2
rs228922 LGALS2
25 30 35
No. of Associations
Body morphology
rs103947 ANXA2
rs35375092 GPX1
rs2275201 MRPL24
rs3826440 RPL26
rs960749 CYBRD1
rs9275314 HLA-DRB4
rs17178396 MAP3K2
rs4970988 RFX5
rs17178720 MAP3K2
rs34928543 HLA-DRB4
8 10 12 14 16
No. of Associations
Disease
rs34928543 HLA-DRB4
rs9275314 HLA-DRB4
rs28746802 HLA-DRB4
rs9271161 HLA-DRB5
rs9271171 HLA-DRB5
rs9270678 HLA-DRB5
rs4386712 PAM
rs11958562 PAM
rs4899565 ACYP1
rs4970988 RFX5
25 50 75
No. of Associations
Immune system
rs9271161 HLA-DRB5
rs9270678 HLA-DRB5
rs9271171 HLA-DRB5
rs9275314 HLA-DRB4
rs6657388 RFX5
rs4970988 RFX5
rs34928543 HLA-DRB4
rs28746802 HLA-DRB4
rs2292401 ACPL2
rs17826037 OAS2
25 50 75
No. of Associations
Neuro-behavioral
rs35375092 GPX1
rs11958562 PAM
rs10085705 C7orf44
rs17654257 C7orf44
rs11588837 HIST2H2AA3,HIST2H2AA4
rs4386712 PAM
rs11901568 ZAP70
rs3754885 ZAP70
rs419099 PAM
rs10784359 AK026751
6 9 12 15
No. of Associations
Nutrition
rs34928543 HLA-DRB4
rs6657388 RFX5
rs9271171 HLA-DRB5
rs9270678 HLA-DRB5
rs4970988 RFX5
rs35406858 COX5A | IMP3
rs9271161 HLA-DRB5
rs103947 ANXA2
rs13040726 C20orf3
rs7116921 RBM4
1 2 3 4 5
No. of Associations
Other
rs35375092 GPX1
rs6657388 RFX5
rs34928543 HLA-DRB4
rs11588837 HIST2H2AA3,HIST2H2AA4
rs56125600 HIST2H2AA3,HIST2H2AA4
rs11958562 PAM
rs11123840 RNF149
rs12417156 PAAF1
rs4970988 RFX5
rs41291223 LAMP1 | CDC16
3 6 9
No. of Associations
dex SNP-DREs
dex-veh SNP-DREs
veh SNP-DREs